Replies to post #193397 on Biotech Values

[DewDiligence]

One negative for CELG-RCPT—>Gilenya goes off-patent in US in Feb 2019:

http://t.co/CFaTZxqJ37

#8324283 is a non-blocking formulation patent.

[DewDiligence]

CELG pop today doesn’t necessarily mean other big biotech acquisitions will follow imminently:

.@rob_cyran @adamfeuerstein 2 keys: $CELG not using stock or paying tax 2repatriate ex-US cash. So I wouldn't paint w unduly broad brush.

— Roy Friedman (@DewDiligence) July 15, 2015